133 Results for "

PLK1

" in MedChemExpress (MCE) Product Catalog:
Products (133)

133 Results for "PLK1" in MCE Product Catalog:

Cat. No.: HY-159493
Research Areas:  

Cancer

BI2536-PEG2-Halo is a bifunctional molecule containing a ligand for Halo tag and a Polo-like kinase 1 (PLK1) inhibitor BI-2536 (HY-50698). BI2536-PEG2-Halo inhibits the proliferation of 293T cells with Halo-p53R273H(FL)-mCherry tag (IC50=23 nM), exhibits selective toxicity against p53 mutant cancer cells [1].
loading...
    loading...
Cat. No.: HY-P71549
Purity:  ≥ 90%, as determined by reducing SDS-PAGE.
Synonyms: STK11; Serine/Threonine Kinase 11 (Peutz-Jeghers Syndrome); Serine/Threonine Kinase 11; Non-Specific Serine/Threonine Protein Kinase; LKB1; Serine/Threonine-Protein Kinase LKB1; PJS; Serine/Threonine-Protein Kinase PLK1; Serine/Threonine-Protein Kinase ST
Species:  
Human
Source:  
E. coli
loading...
    loading...
Cat. No.: HY-101488R
CAS No.: 1010100-07-8
CC-885 (Standard) is the analytical standard of CC-885 (HY-101488). This product is intended for research and analytical applications. CC-885, a cereblon (CRBN) modulator, acts as a molecular glue degrader targeting GSPT1 with a Kd of 350 nM. CC-885 binds to CRBN to alter the substrate specificity of the CRL4 E3 ligase, promoting the ubiquitination and proteasomal degradation of GSPT1, BNIP3L, PLK1, CDK4, IKZF1/3, GSPT2, WIZ, CHD7, GOLM1, CK1α and ETS1. CC-885 induces apoptosis, cell cycle arrest, transcriptional downregulation and antiproliferation in cancer cells. CC-885 is applicable to research related to relapsed/refractory acute myeloid leukemia, MYC-driven tumors, metastatic castration-resistant prostate cancer, multiple myeloma, hepatocellular carcinoma, glioblastoma, VHL-deficient clear cell renal cell carcinoma and non-small cell lung cancer [1] .
loading...
    loading...
Cat. No.: HY-153519
CAS No.: 2869057-11-2
Research Areas:  

Cancer

WWL0245 is a potent and seletive BRD4 PROTAC. WWL0245 selectively degrades BRD4 with sub-nanomolar DC50 (<1 nM) than BRD2/3 and PLK1 ( DC50>1 μM). WWL0245 shows excellent selective cytotoxicity in the BETi sensitive cancer cell lines, including AR-positive prostate cancer cell lines. WWL0245 is a promising drug candidate for AR-positive prostate cancer research and a valuable tool compound to study the biological function of BRD4 [1].
loading...
    loading...
Cat. No.: HY-133703
CAS No.: 2101954-45-2
Target:  

Wee1

Research Areas:  

Cancer

AZD1775-C3-NH2 is a Target Protein Ligand-Linker Conjugate that contains a target protein ligand and a PROTAC linker, and can recruit E3 ligases. AZD1775-C3-NH2 can be used for the synthesis of Pomalidomide-C3-adavosertib (HY-133618) [1].
loading...
    loading...
Cat. No.: HY-133703A
CAS No.: 2858813-30-4
Target:  

Wee1

Research Areas:  

Cancer

i-AZD1775 TFA is a Target Protein Ligand-Linker Conjugate that contains a target protein ligand and a PROTAC linker, and can recruit E3 ligases. i-AZD1775 TFA can be used for the synthesis of Pomalidomide-C3-adavosertib (HY-133618). i-AZD1775 TFA is an immobilizable analogue of AZD1775. i-AZD1775 TFA retains the ability to inhibit WEE1 in vitro. i-AZD1775 TFA can be studied in anticancer research [1].
loading...
    loading...
Cat. No.: HY-124761
CAS No.: 683808-78-8
Research Areas:  

Cancer

Poloppin is a potent, cell penetrant inhibitor of the mitotic Polo-like kinase (PLK) (IC50=26.9 μM) and prevents the protein-protein interaction via the Polo-box domain (PBD) (Kd= 29.5 μM). Poloppin selectively kills cells expressing mutant KRAS, enhancing death in mitosis. Poloppin is used for the study of KRAS-mutant cancers as single agents, or in combination with c-MET inhibitors [1].
loading...
    loading...
Cat. No.: HY-120264
CAS No.: 1964457-41-7
Target:  

Zinc Finger Protein

Research Areas:  

Cancer

YPC-22026 is a zinc-finger protein 143 (ZNF143) inhibitor with an IC50 value of 9.0 μM. YPC-22026 is a potent tumor regression inducer. YPC-22026 exhibits anti‐tumor activities [1].
loading...
    loading...
Cat. No.: HY-184191
CAS No.: 1185003-32-0
Research Areas:  

Cancer

PGK1-IN-3 is an orally active PGK1 inhibitor with human PGK1 IC50 values of 0.48 μM and human PGK1 Kd of 63 nM. PGK1-IN-3 binds to the ADP-binding pocket of PGK1, inhibits glycolysis, and reduces glucose consumption and lactate production. PGK1-IN-3 can be used for the research of pancreatic cancer [1].
loading...
    loading...
Cat. No.: HY-W007287
CAS No.: 30465-68-0
Target:  

Drug Intermediate

Research Areas:  

Cancer

5-Methoxyquinolin-8-amine is an intermediate. 5-Methoxyquinolin-8-amine can be used to synthesize SND1 inhibitors. 5-Methoxyquinolin-8-amine is applicable to breast cancer-related research [1].
loading...
    loading...
Cat. No.: HY-187810
Synonyms: LC-04-118
Research Areas:  

Cancer

dWBP4-1 (LC-04-118) is a CRBN-dependent molecular glue degrader targeting WBP4. dWBP4-1 binds to the IMiD site of CRBN via its glutarimide ring, induces the formation of the CRBN-WBP4 ternary complex (EC50 = 224 nM), and mediates the rapid degradation of WBP4 through the G-loop dependent ubiquitin-proteasome pathway, a process that can be rescued by MLN4924 (HY-70062), Lenalidomide (HY-A0003) or Bortezomib (HY-10227). dWBP4-1 causes almost no perturbation at the transcriptome and alternative splicing levels, exhibits no obvious cytotoxicity, and produces no hook effect. dWBP4-1 can be used for the construction of chemical genetic protein degradation platforms and research related to acute T-lymphoblastic leukemia [1].
loading...
    loading...
Cat. No.: HY-12135
CAS No.: 1239513-63-3
Research Areas:  

Cancer

Poloxipan is a pan-specific polo-like kinase (PLK) inhibitor that can inhibit a non-catalytic region at the C-terminus called the Polo-box domain (PBD) found in kinases. The IC50 values for Poloxipan against the PBDs of PLK-1/2/3 are 3.2 μM, 1.7 μM, and 3.0 μM, respectively. Poloxipan also inhibits other phospho-tyrosine binding domains, such as the forkhead-associated (FHA) domain of CHK-2, the WW domain of peptidyl-prolyl cis/trans isomerase (PIN1), and the phospho-tyrosine binding domains of STAT1/3/5 and lymphocyte-specific protein tyrosine kinase's SH2 domain. Poloxipan can be used in cancer research [1].
loading...
    loading...
Cat. No.: HY-183965
Research Areas:  

Cancer

PLK3-IN-1 is a selective Polo-like kinase 3 (PLK3) inhibitor with a human PLK3 IC50 of 5 nM. PLK3-IN-1 can be used for cancer research [1].
loading...
    loading...